PREDQ
Predictive Technology Group, Inc.

Previously President, Sagent Technologies (medical device division of Sagent Pharmaceuticals), CEO/Co-Founder of Infusive Technologies (developer of drug delivery technologies) and Director/Co-Founder of Specialized Health Products, Inc., acquired by C.R. Bard, Inc. Mr. Robinson studied accounting at the University of Utah and received a Masters of International Management from the Thunderbird, The American Graduate School of International Management.

Paul Evans serves as the Chief Operating Officer at Predictive Technology Group. Mr. Evans has more than 20 years of experience working as a business executive across multiple areas of expertise within the healthcare industry, including intellectual property, corporate governance and compliance, complex commercial transactions, and corporate / business development. Prior to Predictive, he served as vice president of intellectual property at Vivint, Inc., and at InTouch Health served as general counsel and executive vice president of corporate development, chief governance and compliance officer. Mr. Evans also served as general counsel at Specialized Health Products International, Inc., which was acquired by C.R. Bard. Mr. Evans received a B.S. in Mechanical Engineering, J.D., and M.B.A. degrees from the University of Utah.

Mr. Sorrentino is Vice-President and Chief Operating Officer of Vaccine Research and Development at Pfizer. During his more than 35 years of senior management experience in the life sciences industry, Mr. Sorrentino has held leadership roles in private and public companies, as well as government and non-profit institutions, with a focus on improving public health. Prior to joining Wyeth (acquired by Pfizer) 14 years ago, Mr. Sorrentino held executive positions in several organizations that provided neonatal screening and related clinical services. Mr. Sorrentino's expertise has had him appear before state legislators, the US Congress and professional societies on a variety of healthcare and policy issues. Mr. Sorrentino brings significant leadership experience in R&D, commercialization and clinical laboratory management that are valuable additions to the Company's Board of Directors

Ronald Barhorst serves as a member on the financial advisory board at Predictive Technology Group. He is also chair of the California State University Foundation. Prior to Predictive, he served as president and chief executive officer of ING Financial Advisers, LLC., ING Investment Advisors, LLC., and Systematized Benefits Administrators, Inc. At ING he led national accounts, healthcare and government markets. Prior to that, Mr. Barhorst served as director of residential services for Montgomery County Board of Mental Retardation and Development Disabilities and as treasurer for the Ohio Private Residential Services Association and executive director of Choices in Community Living, a non-profit organization he founded. He has also served on numerous non-profit boards, including the California Business Roundtable for Education Excellence. Mr. Barhorst earned his bachelor’s degree from Wright State University.

Michael Dey is a member on the board of directors at Predictive Technology Group. Dr. Dey also serves as a member on the scientific advisory board at Coactigon, Inc. and GenBioPro, Inc. as well as a consultant, providing marketing, scientific, and technical insight and guidance for the development of new chemical entities and marketed products for new indications. Prior to Predictive, he was a member on the board of directors for Juneau Biosciences, and at Wyeth Pharmaceuticals, served as president of scientific affairs and women’s health care where he was the Company’s principal corporate witness in ongoing breast cancer litigation and provided oversight and direction on the development of estrogen products. Dr. Dey also held multiple leadership roles at Wyeth-Ayerst Laboratories where he led a new generic drug division that developed, manufactured, and marketed generic oral and parenteral treatments. He has authored and co-authored eighteen manuscripts and holds seven patents. Dr. Dey received his doctoral degree in pharmacology/toxicology from Washington State University.

Previously President, Sagent Technologies (medical device division of Sagent Pharmaceuticals), CEO/Co-Founder of Infusive Technologies (developer of drug delivery technologies) and Director/Co-Founder of Specialized Health Products, Inc., acquired by C.R. Bard, Inc. Mr. Robinson studied accounting at the University of Utah and received a Masters of International Management from the Thunderbird, The American Graduate School of International Management.